Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224802 · ClinicalTrials.gov registry record
Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 372
- Enrollment target
NCT07224802: Completed study, sponsored by City of Hope Medical Center.
NCT07224802 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 372 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224802 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 372 participants
- Enrollment target
Study Summary
Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinical need. The EXELiM study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to accurately identify PDAC patients at high risk of occult liver metastasis before surgery. By integrating machine learning with multi-institutional plasma exosome profiling, this study seeks to enable biology-driven patient stratification and guide treatment sequencing toward precision oncology.
Primary Outcome
True Negative Rate: probability of a negative test result conditioned on absence of early liver metastasis
Interventions
- DIAGNOSTIC_TEST EXELiM assay (qRT-PCR validation)
- DIAGNOSTIC_TEST EXELiM small RNA sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-02-18 |
What the finished NCT07224802 record still lists
NCT07224802 is an observational study that tracks outcomes without assigning an intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which EXELiM assay (qRT-PCR validation) is the first listed.
NCT07224802 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07224802 about?
NCT07224802 is a clinical study titled "Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting". Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinical need. The EXELiM ...
What is the current status of trial NCT07224802?
This trial is currently completed. The enrollment target is 372 participants. The study started on 2024-06-21. Estimated completion is 2026-02-18.
What interventions are being tested in trial NCT07224802?
The interventions under investigation include: EXELiM assay (qRT-PCR validation) (DIAGNOSTIC_TEST), EXELiM small RNA sequencing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07224802?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI